S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
NASDAQ:AZN

AstraZeneca (AZN) Stock Forecast, Price & News

$67.72
+0.30 (+0.44%)
(As of 09/29/2023 ET)
Compare
Today's Range
$67.58
▼
$68.78
50-Day Range
$66.45
▼
$71.70
52-Week Range
$53.52
▼
$76.56
Volume
3.69 million shs
Average Volume
4.18 million shs
Market Capitalization
$209.92 billion
P/E Ratio
34.03
Dividend Yield
1.34%
Price Target
$80.00
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

AstraZeneca MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
18.1% Upside
$80.00 Price Target
Short Interest
Healthy
0.27% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.75mentions of AstraZeneca in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.48%
From $3.66 to $4.19 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

159th out of 970 stocks

Pharmaceutical Preparations Industry

53rd out of 450 stocks

See Top Rated MarketRank™ Stocks Here

AZN stock logo

About AstraZeneca (NASDAQ:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Price History

AZN Stock News Headlines

September 25, 2023 | marketbeat.com
Argenx's 28% Surge & Promising Product Propel Investor Confidence (AZN)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
September 30, 2023 | reuters.com
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
September 30, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
September 29, 2023 | uk.style.yahoo.com
Which is the best value stock now: AstraZeneca or GSK?
September 26, 2023 | markets.businessinsider.com
AstraZeneca Share Price: New Buy Ratings Predict Upside
September 26, 2023 | americanbankingnews.com
AstraZeneca (NASDAQ:AZN) Upgraded to "Buy" at Jefferies Financial Group
September 25, 2023 | msn.com
AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study
September 25, 2023 | uk.news.yahoo.com
AstraZeneca stock upgraded to Buy at Jefferies
September 30, 2023 | Weiss Ratings (Ad)
These cryptos could skyrocket by January
After the massive market collapse and several huge scandals last year, a lot of experts are saying the crypto markets are just one more step away from going to zero. But are they right?
September 25, 2023 | proactiveinvestors.com
AstraZeneca upgraded on potential for non-oncology assets
September 25, 2023 | msn.com
Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and more
September 22, 2023 | finance.yahoo.com
AstraZeneca Surges As It Takes A Shot At Gilead's Second-Biggest Cancer Drug
September 22, 2023 | msn.com
AstraZeneca Stock Rises on Positive Trial Results for Breast Cancer Drug
September 22, 2023 | msn.com
AstraZeneca ADSs Rise After Reporting Positive Results in Breast Cancer Drug Trial
September 22, 2023 | baystreet.ca
AstraZeneca Moves Higher on Cancer Drug Tests
September 22, 2023 | benzinga.com
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023 | msn.com
London stocks slip on concerns over higher-for-longer rates; AstraZeneca gains
September 22, 2023 | markets.businessinsider.com
AstraZeneca Reports Positive Results From Phase III Trial With Datopotamab Deruxtecan
September 22, 2023 | reuters.com
AstraZeneca and Daiichi's breast cancer drug meets goal in study
September 21, 2023 | finance.yahoo.com
Astrazeneca (AZN) Stock Moves -1.38%: What You Should Know
September 20, 2023 | msn.com
AstraZeneca refused to pay full bonus to US remote worker, lawsuit claims
September 20, 2023 | americanbankingnews.com
Traders Purchase High Volume of AstraZeneca Put Options (NASDAQ:AZN)
September 18, 2023 | finance.yahoo.com
CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
September 15, 2023 | markets.businessinsider.com
AstraZeneca's Enhertu Recommended For Approval In EU For Advanced Non-small Cell Lung Cancer
September 15, 2023 | finance.yahoo.com
Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know
September 12, 2023 | finance.yahoo.com
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
September 12, 2023 | markets.businessinsider.com
AZN : Phase III Trial Of FASENRA In Eosinophilic Granulomatosis With Polyangiitis Meets Main Goal
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Company Calendar

Last Earnings
7/28/2023
Ex-Dividend for 9/11 Dividend
8/10/2023
Dividend Payable
9/11/2023
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZN
CUSIP
N/A
CIK
901832
Web
www.astrazeneca.com
Phone
442037495000
Fax
44-12-2335-2858
Employees
83,500
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$80.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$80.00
Forecasted Upside/Downside
+18.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.99
Trailing P/E Ratio
34.03
Forward P/E Ratio
18.50
P/E Growth
1.34
Net Income
$3.29 billion
Net Margins
13.86%
Pretax Margin
13.60%
Return on Equity
30.39%
Return on Assets
11.51%

Debt

Debt-to-Equity Ratio
0.65
Current Ratio
0.87
Quick Ratio
0.67

Sales & Book Value

Annual Sales
$44.49 billion
Price / Sales
4.72
Cash Flow
$5.11 per share
Price / Cash Flow
13.24
Book Value
$11.96 per share
Price / Book
5.66

Miscellaneous

Outstanding Shares
3,099,795,000
Free Float
N/A
Market Cap
$209.92 billion
Optionable
Optionable
Beta
0.50

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Pascal Soriot D.V.M.Mr. Pascal Soriot D.V.M. (Age 64)
    M.B.A., CEO & Exec. Director
    Comp: $5.92M
  • Dr. Aradhana Sarin M.D.Dr. Aradhana Sarin M.D. (Age 48)
    Exec. Director
    Comp: $3.39M
  • Ms. Pam P. ChengMs. Pam P. Cheng (Age 52)
    EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
  • Mr. Andrew P. Barnett
    Head of Investor Relations
  • Mr. Jeffrey Pott
    CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D.Dr. Menelas Pangalos Ph.D. (Age 56)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
  • Dr. Susan Mary Galbraith M.D. (Age 57)
    Ph.D., Exec. VP of Oncology R&D
  • Mr. Leon Wang
    Exec. VP of International & China Pres

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2023?

7 brokers have issued 12 month price objectives for AstraZeneca's shares. Their AZN share price forecasts range from $80.00 to $80.00. On average, they anticipate the company's stock price to reach $80.00 in the next year. This suggests a possible upside of 18.1% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at $67.80 on January 1st, 2023. Since then, AZN stock has decreased by 0.1% and is now trading at $67.72.
View the best growth stocks for 2023 here.

When is AstraZeneca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our AZN earnings forecast.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) issued its earnings results on Friday, July, 28th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.97 by $0.11. The company had revenue of $11.42 billion for the quarter, compared to analyst estimates of $11.06 billion. AstraZeneca had a trailing twelve-month return on equity of 30.39% and a net margin of 13.86%.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Friday, July 28th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.465 per share on Monday, September 11th. This represents a dividend yield of 2%. The ex-dividend date of this dividend is Thursday, August 10th.
Read our dividend analysis for AZN.

What ETFs hold AstraZeneca's stock?

ETFs with the largest weight of AstraZeneca (NASDAQ:AZN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), VanEck Pharmaceutical ETF (PPH), PGIM Jennison Focused Value ETF (PJFV), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), Global X Aging Population ETF (AGNG), Clockwise Capital Innovation ETF (TIME) and Emerge EMPWR Sustainable Global Core Equity ETF (EMZA).

Is AstraZeneca a good dividend stock?

AstraZeneca (NASDAQ:AZN) pays an annual dividend of $0.91 per share and currently has a dividend yield of 1.34%. The dividend payout ratio is 45.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AZN will have a dividend payout ratio of 21.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AZN.

When did AstraZeneca's stock split?

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Moderna (MRNA), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Albertsons Companies (ACI), American Airlines Group (AAL), Blue Apron (APRN), BlackBerry (BB), Brookfield Infrastructure Partners (BIP), CymaBay Therapeutics (CBAY) and Carnival Co. & (CCL).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the NASDAQ under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $67.72.

How much money does AstraZeneca make?

AstraZeneca (NASDAQ:AZN) has a market capitalization of $209.92 billion and generates $44.49 billion in revenue each year. The company earns $3.29 billion in net income (profit) each year or $1.99 on an earnings per share basis.

How many employees does AstraZeneca have?

The company employs 83,500 workers across the globe.

Does AstraZeneca have any subsidiaries?
The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More
How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The official website for the company is www.astrazeneca.com. The company can be reached via phone at 442037495000, via email at ir@astrazeneca.com, or via fax at 44-12-2335-2858.

This page (NASDAQ:AZN) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -